1. Scrip

Organon's First Move Post Spinout Is A Licensing Deal With ObsEva In Preterm Labor

 
• By Jessica Merrill

Ogranon will pay $25m upfront for worldwide commercialization rights to ebopiprant for acute preterm labor, which currently has no approved treatments in the US.

women's handshake
Organon partnered with ObsEva in women's health • Source: Alamy

Organon is making good on its promise to investors that it will build out its women's health portfolio. The company announced its first licensing deal on 27 July, in its second month after spinning out from Merck & Co. Organon bought worldwide licensing rights to ebopiprant for acute preterm labor in a deal with Swiss women's health specialist ObsEva SA.

Ebopiprant is a potential first-in-class selective prostaglandin F2α (PGF2α) receptor antagonist that could treat preterm labor by reducing inflammation and uterine contractions. There are currently no approved therapies for acute preterm labor in the US

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.